Annahita Keravala, PhD

Annahita Keravala, PhD has a diverse and extensive work experience in the field of biotechnology and gene therapy. Annahita started their career at the University of Pittsburgh School of Public Health as a graduate student from 1998 to 2003. Following this, they joined Stanford University School of Medicine as a post-doctoral scholar, where they led pre-clinical research on gene and cell therapy using the PhiC31 Integrase Technology. Annahita conducted pivotal non-viral gene delivery experiments in various stem cells and studied the kinetics and safety of PhiC31 integrase technology.

In 2008, Annahita joined Stanford University as a research scientist before moving to Geron in 2010, where they worked as a scientist. Annahita then joined Adverum Biotechnologies in 2013 and held several roles, including Senior Scientist, Group Leader of Research, and Director of Novel Vector Technologies.

In 2018, Annahita transitioned to Rocket Pharmaceuticals, where they served as the Associate Vice President of AAV Gene Therapy Platform until 2019. Annahita then joined CODA Biotherapeutics as the Senior Vice President of Gene Therapy from November 2019 to September 2022.

Currently, Annahita holds the position of Chief Scientific Officer at Genascence Corporation, starting in October 2022. In summary, Annahita Keravala's work experience spans various positions of increasing responsibility and expertise in gene therapy and biotechnology.

Annahita Keravala, PhD has a strong educational background in the field of life sciences and biotechnology. From 1993 to 1996, they attended St. Xavier's College, where they earned a Bachelor of Science degree in Biochemistry. Following this, from 1996 to 1998, Annahita pursued a Master of Science degree in Biotechnology at the University of Mumbai. Annahita then enrolled at the University of Pittsburgh School of Medicine, where they obtained their Ph.D. from 1998 to 2003, specializing in Gene Therapy for Rheumatoid Arthritis. Annahita furthered their education at Stanford University School of Medicine, where they became a Post-doctoral Scholar from 2003 to 2008, focusing on Gene Therapy utilizing phiC31 integrase.